CLAIMS

1. Isolated or synthetic RNA sequence comprising sequence SEQ ID NO: 1 or a SEQ ID NO:1 orthologous sequence.

2. RNA sequence for use according to claim 1, characterized in that said orthologous sequence is of human origin and consists in sequence SEQ ID NO: 2 or is of mouse origin and consists in a sequence chosen from among SEQ ID NO: 3 and SEQ ID NO: 4.

3. RNA sequence for use according to claim 1 or 2, characterized in that said sequence is a small nucleolar RNA (snoRNA).

4. RNA sequence for use according to claim 1, characterized in that said functionally–analogous sequence permits splicing a *Drosophila melanogaster* gene chosen from among Ir56d, buttonhead, klarsicht, CG3262, CG30502 (*fa2h*), CG11125, CG9339 and CG40006.

5. DNA sequence coding for an RNA sequence according to one of claims 1 to 4 for use as a medicament.

6. Vector allowing the expression of an RNA sequence according to one of claims 1 to 4 for use as a medicament, wherein the vector is chosen, for example, from among a plasmid, a cosmid, a viral vector and a phage, and wherein the vector preferably comprises a promotor and/or regulator elements promoting the expression of said RNA sequence in intestinal or ovarian cells.

7. Cell comprising a RNA sequence according to one of claims 1 to 4 for use as a medicament or cell transformed using a vector as described in claim 6 for use as a medicament.

8. Composition comprising a RNA sequence for use according to one of claims 1 to 4, a vector for use according to claim 6 or a cell for use according to claim 7 and a dietarily- or pharmaceutically–acceptable support.

9. Use of a RNA sequence according to one of claims 1 to 4, of a vector according to claim 6, of a cell according to claim 7 or of a composition according to claim 8, continuously or sequentially, to restore or modulate the expression of said RNA sequence *in vitro* or *ex vivo*.

10. Transgenic mouse in the genome of which one and/or the other of sequences SEQ ID NO: 3 and SEQ ID NO: 4 have been modified to prevent or modify the expression of one and/or the other of said sequences.

11. Use of the RNA sequence according to one of claims 1 to 4 in the preparation of a medicament for the prevention or treatment of a neurodegenerative disease induced by mutation of the fah2 gene, a laminopathy, diabetes, obesity or cancer in a subject.

12. The use according to claim 11 wherein the cancer is a cancer induced by free radicals.

13. Use of the RNA sequence according to one of claims 1 to 3 in the preparation of a medicament for the treatment of sterility or infertility in a subject.

14. The use according to one of claims 11 to 13, characterized in that the subject is an animal or insect, typically a mammal, preferably a human, even more preferably a subject not expressing the RNA sequence according to one of claims 1 to 3 or expressing an abnormal version of said RNA sequence, and/or a subject suffering from a neurodegenerative disease induced by mutation of the fah2 gene, a laminopathy, diabetes, obesity, a cancer or a fertility problem.

15. The use according to claim 14, characterized in that the genome of the subject, not expressing the RNA according to one of claims 1 to 3 or expressing an abnormal version of said RNA sequence, contains a DNA sequence comprising a mutation, said sequence being in the wild state chosen from among SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7 and SEQ ID NO: 8; and said mutation being preferably chosen from among a deletion, substitution or addition of one or more base pairs.